Research - News
A national report co-written by a UAB dentist found that dentists who were assumed to be at increased risk of COVID exposure had a less than 1 percent infection rate of COVID-19.
A monoclonal antibody is being developed by Aridis Pharmaceuticals as an inhaled, self-administered treatment for non-hospitalized patients who are suffering from mild to moderate COVID-19.
New recommendations for treatment and prevention of HIV infection in adults will help guide physicians and patients in HIV therapies and treatment regimens.
UAB will build an autonomous vehicle mobility facility that works in collaboration with its Engineering and Innovative Technology Development research group.
Integration of the telehealth platform in a multiphase optimization strategy evaluation will allow researchers to develop behavioral health approaches that are more realistic and tailored to the individual’s goals and health needs.
UAB’s new cystic kidney disease core center will spearhead a multidisciplinary approach to finding treatments for this devastating disease
The vaccine candidate Altimmune’s AdCOVID potently stimulated neutralizing antibody and T cell responses, as well as mucosal immunity in the respiratory tract.
Precision disease modeling involves creation of patient-specific disease models that mimic the molecular character of a condition present in a patient, enabling more precise diagnoses and treatments.
UAB researchers will use existing knowledge and research to address urgent needs for rapid SARS-CoV-2 testing among underserved populations.
The virus responsible for COVID-19 seems to have an affinity for the heart, leading to concerns for an increase in heart issues among young athletes.
This avenue of basic research will aid understanding of neurodevelopmental disorders in humans.
UAB stands 22nd in the nation in research funding from the National Institutes of Health.
A $1.95 million grant will allow UAB researchers to develop an online tool to help educate children on firearms safety.
The exosomes were secreted by cardiac cells derived from human induced pluripotent stem cells. These non-living exosomes may be an easier form of regenerative treatment than living cells.
The UAB Nathan Shock Center received a $4.5 million grant renewal from the National Institute on Aging to further engage in cutting-edge research focused on comparative bioenergetics and aging.
American Heart Association special report highlights trends in awareness among women in the United States regarding heart disease.
These molecular insights may foster effective therapies using existing drugs for patients with COVID-19.
The grant is designed to bring disparate investigators together, to foster communication and collaboration among researchers.
This study of ischemic stroke patients is the first to associate the neutrophil-lymphocyte ratio in patients with COVID-19 and ischemic stroke and stroke severity.
Researchers at UAB continue leading the way in finding the best personal protective equipment for use.
The entirely transparent mask can be worn as-is or modified with N95 cushioned filters and sensor arms that check for temperature and pulse.
A study conducted by UAB investigators has outlined that Black individuals with heart failure have a worse prognosis, even after achieving biomarker-based heart failure treatment targets.
Failing to account for weaker firearm laws in neighboring states made it falsely appear that a states’ laws were about 20 percent less effective in reducing firearm deaths.
A new grant will look at the effects of aging caused by antiviral therapies in individuals with HIV.
UAB’s exploratory Alzheimer’s Disease Research Center will address a coverage gap in the Deep South of the nation’s ADRC network.
These lipids may act as a biomarker for Type 1 diabetes and offer a therapeutic target to prevent the disease.
Uncontrolled high blood pressure is a risk factor for heart attack and stroke.
A UAB communications expert explains how communication skills have changed during the COVID-19 pandemic quarantine.
The UAB team identified how the poorly understood BIN1 gene might be player in Alzheimer’s disease.
In a new trial funded through UAB’s urgent COVID-19 research program, investigators are comparing the widely available steroid methylprednisolone with dexamethasone, which lowered risk of dying by one-third in a U.K. trial this summer.